BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36697091)

  • 1. Carbon Ion Radiotherapy
    Yamamoto N; Oshima T; Kawahara S; Takahashi D; Kamioka Y; Murakawa M; Katoh H; Ueno M; Morinaga S
    Anticancer Res; 2023 Feb; 43(2):809-815. PubMed ID: 36697091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer.
    Shinoto M; Yamada S; Yasuda S; Imada H; Shioyama Y; Honda H; Kamada T; Tsujii H; Saisho H;
    Cancer; 2013 Jan; 119(1):45-51. PubMed ID: 22744973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy Inhibition Increased Sensitivity of Pancreatic Cancer Cells to Carbon Ion Radiotherapy.
    Sudo M; Tsutsui H; Hayashi S; Yasuda K; Mitani K; Iwami N; Anzai M; Tsubouchi T; Ishida M; Satoi S; Kanai T; Hirono S; Hatano E; Fujimoto J
    Cell Physiol Biochem; 2023 Jul; 57(4):212-225. PubMed ID: 37463410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study.
    Su YY; Chao YJ; Wang CJ; Liao TK; Su PJ; Huang CJ; Chiang NJ; Yu YT; Tsai HM; Chen LT; Shan YS
    Int J Surg; 2023 Sep; 109(9):2614-2623. PubMed ID: 37300888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Oncologic Outcomes and Treatment-Related Toxicity of Carbon Ion Radiotherapy and En Bloc Resection for Sacral Chordoma.
    Yolcu YU; Zreik J; Wahood W; Bhatti AUR; Bydon M; Houdek MT; Rose PS; Mahajan A; Petersen IA; Haddock MG; Ahmed SK; Laack NN; Jethwa K; Jeans EB; Imai R; Yamada S; Foote RL
    JAMA Netw Open; 2022 Jan; 5(1):e2141927. PubMed ID: 34994795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report.
    Watanabe Y; Tatsuguchi T; Date K; Shinkawa T; Kuga H; Tamiya S; Nishihara K; Nakano T
    J Med Case Rep; 2024 Jan; 18(1):13. PubMed ID: 38200536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases.
    Lee JM; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
    J Surg Oncol; 2023 Sep; 128(4):549-559. PubMed ID: 37288777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study.
    Vitolo V; Cobianchi L; Brugnatelli S; Barcellini A; Peloso A; Facoetti A; Vanoli A; Delfanti S; Preda L; Molinelli S; Klersy C; Fossati P; Orecchia R; Valvo F
    BMC Cancer; 2019 Sep; 19(1):922. PubMed ID: 31521134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
    Hoffe S; Rao N; Shridhar R
    Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
    Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
    J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
    Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbon-Ion Radiotherapy Combined with Concurrent Chemotherapy for Locally Advanced Pancreatic Cancer: A Retrospective Case Series Analysis.
    Okamoto M; Shiba S; Kobayashi D; Miyasaka Y; Okazaki S; Shibuya K; Ohno T
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy.
    Kurahara H; Mataki Y; Idichi T; Iino S; Kawasaki Y; Arigami T; Mori S; Sasaki K; Shinchi H; Ohtsuka T
    Ann Surg Oncol; 2021 Oct; 28(11):6238-6245. PubMed ID: 33606140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
    BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.